AsiaTIDES Conference & Exhibition

Register by this Friday, January 13 to save USD200 off your registration.

Visit www.IBCLifeSciences.com/AsiaTIDES/pricing.xml for full details.

IBC's 4th Annual

AsiaTIDES: Oligonucleotide and Peptide® Research, Technology and Product Development

February 28 - March 1, 2012 • Sheraton Miyako Hotel • Tokyo, Japan

Conference Brochure

Download Conference Brochure

Attendee Praise

"A very well prepared and well organized meeting with outstanding lectures in peptide and oligonucleotide chemistry. A visit to the next meeting is highly recommended."

- Peter Lewandrowski, Ph.D., Director and Head of CMC, immatics biotechnologies GmbH, Germany

"AsiaTIDES is the unique conference that offers the players (pharma, biotechs and CMOs) a great overview of the 'tides' field. As usual in this conference, excellent papers are presented and this is a very good networking opportunity."

- Mimoun Ayoub, Ph.D., Vice President, Strategic Development, Peptisyntha, Member of the SOLVAY Group, Belgium

"TIDES and AsiaTIDES are great places to follow up, to trace peptide clinical trials and regulatory updates... A 'must attend.'"

- Shawn Lee, President and CEO, CPC Scientific Inc., USA

IBC Life Sciences' upcoming 4th Annual AsiaTIDES Conference & Exhibition is the only event in Asia with comprehensive updates on therapeutics in development from major big pharma, biotech and academic scientists worldwide.

Click here to download a copy of the brochure (PDF).

Conference Highlights

More representation from big pharma than ever before.
Hear new data and strategic perspectives from Merck, Genzyme, and GlaxoSmithKline, including three presentations from Glaxo on a peptide project and their assessments of both the oligo and peptide landscape.

A robust field of keynote presentations, including an update on the clinical development of mipomersen from Genzyme and a look back on 2011 as a pivotal year for oligonucleotide therapeutics by Arthur Levin of Santaris A/S.

Pre-conference tutorials to increase your knowledge:

  • Technical and Regulatory Aspects of Peptide Specifications and Characterization: From Preclinical through to Market Application
  • Strategies and Approaches for in vivo Delivery of Oligonucleotides

Brand new regulatory session on preclinical safety assessment, including an update from the Oligo Safety Working Group and – new this year – 2 talks from the JPMA.

Unpublished new data on the Combinatorial Development of Biomaterials and Synthetic siRNA Delivery Systems by Dan Anderson, Associate Professor of Chemical Engineering at Massachusetts Institute of Technology.

Two timely presentations on peptide-based vaccines:

  • (CASE STUDY) Design Considerations for DPX-Survivac, a Multi-Cancer Peptide-Based Vaccine
  • (UNPUBLISHED DATA) Speeding up Peptide-Based Vaccine Research with VesiVax® Conjugatable Adjuvant Lipid Vesicles (CALV)

An insightful talk on Pharmaceutical Protein and Peptide Engineering by Jesper Lau, Vice President of Diabetes Protein and Peptide Chemistry at Novo Nordisk, Denmark

Glaxo’s CMC perspective on industrialising a therapeutic oligo portfolio presented by Mike Webb, Head of API Chemistry and Analysis at GSK UK

Premier Publication:

BioProcess International